Observational studyBreast cancer (Tokyo, Japan)2026
Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan.
Observational study in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Interstitial Lung Disease and Cardiotoxicity Associated with Trastuzumab Deruxtecan, Sacituzumab Govitecan, and Trastuzumab Emtansine: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Toxicities of Antibody-Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management.Pharmaceutics · 2026Review
- Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease.Breast (Edinburgh, Scotland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundWhile trastuzumab deruxtecan (T-DXd) shows efficacy in various cancers, interstitial lung disease (ILD) and pneumonitis are significant risks associated with its use. Understanding these risks is crucial for effective management and safe administration of T-DXd. Therefore, we conducted a postmarketing surveillance study in Japan to investigate the incidence of ILD and related factors.
methodsAll patients with human epidermal growth factor receptor 2-positive unresectable or recurrent breast cancer who initiated T-DXd in Japan between May 25, 2020, and November 30, 2021, were included. The primary outcome was the incidence of adjudicated drug-related ILD, and its associated factors were investigated using a Cox proportional hazards model.
resultsThe safety analysis set included 1,731 patients with a median (range) age of 60 (27–87) years. The median (range) duration of T-DXd treatment was 9.4 (0.7–17.9) months. A total of 24 (1.4%) and 11 (0.6%) patients had ILD as a medical history and comorbidity, respectively. The incidence of any Grade, Grade ≥ 3, and Grade 5 adjudicated drug-related ILD was 16.1%, 3.0%, and 1.0%, respectively. The median (range) time from the first T-DXd treatment to the first onset of ILD was 5.1 (0.5–17.3) months. Male sex, higher body mass index (≥ median [21.3 kg/m2]), history/comorbidity of ILD, and impaired renal function were identified as baseline factors potentially associated with an increased risk of drug-related ILD.
conclusionsThe incidence of adjudicated drug-related ILD in the real-world setting was similar to that observed in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.